Literature DB >> 16382068

Aromatase inhibitors--a triumph of translational oncology.

Sandra M Swain.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16382068     DOI: 10.1056/NEJMe058273

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.

Authors:  Gauri J Sabnis; Olga Goloubeva; Saranya Chumsri; Nguyen Nguyen; Saraswati Sukumar; Angela M H Brodie
Journal:  Cancer Res       Date:  2011-01-18       Impact factor: 12.701

2.  Variable phenotypes associated with aromatase (CYP19) insufficiency in humans.

Authors:  Lin Lin; Oya Ercan; Jamal Raza; Christine P Burren; Sarah M Creighton; Richard J Auchus; Mehul T Dattani; John C Achermann
Journal:  J Clin Endocrinol Metab       Date:  2006-12-12       Impact factor: 5.958

3.  HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.

Authors:  Gauri J Sabnis; Olga G Goloubeva; Armina A Kazi; Preeti Shah; Angela H Brodie
Journal:  Mol Cancer Ther       Date:  2013-10-03       Impact factor: 6.261

4.  Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.

Authors:  Gauri Sabnis; Olga Goloubeva; Rabia Gilani; Luciana Macedo; Angela Brodie
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

Review 5.  Steroid hormone analysis by tandem mass spectrometry.

Authors:  Steven J Soldin; Offie P Soldin
Journal:  Clin Chem       Date:  2009-03-26       Impact factor: 8.327

6.  Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.

Authors:  Ines Barone; Yukun Cui; Matthew H Herynk; Arnoldo Corona-Rodriguez; Cinzia Giordano; Jennifer Selever; Amanda Beyer; Sebastiano Andò; Suzanne A W Fuqua
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

7.  Alopecia with endocrine therapies in patients with cancer.

Authors:  Vishal Saggar; Shenhong Wu; Maura N Dickler; Mario E Lacouture
Journal:  Oncologist       Date:  2013-09-13

8.  Stopping treatment can reverse acquired resistance to letrozole.

Authors:  Gauri J Sabnis; Luciana F Macedo; Olga Goloubeva; Adam Schayowitz; Angela M H Brodie
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

Review 9.  Aromatase inhibitors in early hormone receptor-positive breast cancer : what is the optimal initiation time for the maximum benefit?

Authors:  Sarah J Needleman; Jeffrey S Tobias
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  The discovery and mechanism of action of letrozole.

Authors:  Ajay S Bhatnagar
Journal:  Breast Cancer Res Treat       Date:  2007-10-03       Impact factor: 4.872

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.